Atlas Trials

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Clinical trial NCT01702558 · TERMINATED

Trial details

NCT number
NCT01702558
Sponsor
Hoffmann-La Roche
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerGastric Cancer
Start date
2012-12-03
Primary completion
2017-05-31
Enrollment
182

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.